LYRA - Lyra Therapeutics Inc
Lyra Therapeutics Inc Logo

LYRA - Lyra Therapeutics Inc

https://lyratherapeutics.com
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Lyra Therapeutics, Inc., a clinical-stage therapeutic company, focuses on the development and commercialization of new integrated drug and delivery solutions for the localized treatment of patients with diseases of the ear, nose and throat. The company is headquartered in Watertown, Massachusetts.

52W High
$34.00
52W Low
$3.81
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.17
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.66
EV/Revenue (<3 favorable)
18.13
P/S (TTM) (<3 favorable)
14.63
P/B (<3 favorable)
6.94
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
0.67%
Institutions (25–75% balanced)
38.13%
Shares Outstanding
1,644,400
Float
1,122,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
770,000
Gross Profit (TTM)
-21,480,000
EPS (TTM)
-28.99
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-46.05%
ROE (TTM) (>15% strong)
-2.38%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.69
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—